DNA RNA and Cells

12 Jun 2017 Seres Therapeutics Initiates SER-109 Phase 3 Study in Patients with Multiply Recurrent C. difficile Infection
12 Jun 2017 CARMA Therapeutics Closes Initial Funding to Advance Chimeric Antigen Receptor Macrophages (CARMA) to Treat Solid Tumors
12 Jun 2017 Regulus Announces Pipeline Updates and Advancements
11 Jun 2017 AGTC Announces Topline Safety Data for X-Linked Retinoschisis Phase 1/2 Study
11 Jun 2017 Novartis presents data demonstrating efficacy of AMG 334 (erenumab) in migraine prevention at the American Headache Society Annual Meeting
07 Jun 2017 Rebiotix Data Presented at ASM Microbe 2017 Show RBX2660 Treated Patients' Clinical Success Correlates with Improved Microbiome Diversity
07 Jun 2017 TCR2 Therapeutics to Debut Positive Solid Tumor Data on its Novel TRuC™ Engineered T Cell Platform at the World Preclinical Congress
07 Jun 2017 Eureka Therapeutics and City of Hope Announce Agreement to Conduct Phase 1 Clinical Trial of Investigational ET1402L1 CAR-T Therapy in Liver Cancer
07 Jun 2017 Inovio Zika Vaccine Prevents Persistence of Virus and Damage in Male Reproductive Tract in Pre-Clinical Study
07 Jun 2017 Novartis interim results from global, pivotal CTL019 trial show durable complete responses in adults with r/r DLBCL
05 Jun 2017 ZIOPHARM Oncology Announces Positive Updated Results of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma at the 2017 ASCO Annual Meeting
05 Jun 2017 Poseida Therapeutics Presents High-Fidelity Genome Editing System for Production of Allogeneic "Universal Donor" CAR-T Cells at American Society of Clinical Oncology Annual Meeting
05 Jun 2017 Seres Therapeutics Announces Completion of Enrollment for SER-287 Phase 1b Study in Patients with Ulcerative Colitis
05 Jun 2017 Kite Reports 73 Percent of Patients Achieved MRD Negative Complete Remission in Updated Analysis From Phase 1 ZUMA-3 CAR-T Trial of KTE-C19 in Adult Patients With High Burden Relapsed/Refractory Acute Lymphoblastic Leukemia
05 Jun 2017 bluebird bio and Celgene Corporation Announce Updated Clinical Results from Ongoing First-in-Human Multicenter Study of bb2121 Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting
05 Jun 2017 Juno Therapeutics Presents Updated TRANSCEND NHL 001 Trial Data Demonstrating High Durable Response Rates in Patients with Relapsed or Refractory CD19+ Aggressive Non-Hodgkin Lymphoma
05 Jun 2017 Adaptimmune Announces an Oral Presentation on Data from NY-ESO Study in Synovial Sarcoma and Four Trials in Progress Posters at the American Society of Clinical Oncology (ASCO) Annual Meeting
05 Jun 2017 CARsgen Presents Phase I Results of CAR-GPC3 T HCC Trial at ASCO 2017 Annual Meeting
04 Jun 2017 Amgen Presents New Phase 2 Data On IMLYGIC® (Talimogene Laherparepvec) Investigational Combination At ASCO 2017
02 Jun 2017 Voyager Therapeutics Selects Lead Clinical Candidate for Huntington’s Disease
02 Jun 2017 Sylentis Initiates a Phase III Study for the Treatment of Dry Eye Syndrome
02 Jun 2017 MolMed provides update on Zafiride Conditional Marketing Authorization application
02 Jun 2017 SPINRAZA® (Nusinersen) Approved in the European Union as First Treatment for Spinal Muscular Atrophy
31 May 2017 FDA Grants Breakthrough Therapy Designation for Alnylam’s Givosiran for the Prophylaxis of Attacks in Patients with Acute Hepatic Porphyria
31 May 2017 Novartis next generation CAR-T cell therapy CTL119 combined with ibrutinib shows high rate of responses in CLL patients

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing